Le Lézard
Classified in: Health, Science and technology, Business
Subjects: CON, FNC

CHARAC SECURES £1M INVESTMENT FROM WORLD-CLASS MEDICATION PLATFORM MEDADVISOR TO DRIVE ITS INTERNATIONAL GROWTH


Total capital raised by Charac now sits at £3.5 million following previous investment from the National Pharmacy Association

Deal allows Charac to expand its capabilities across Australia, New Zealand and the USA to help pharmacists capitalise on significant market opportunities

LONDON, Nov. 28, 2023 /PRNewswire/ -- Leading healthcare SaaS provider Charac today announces a ground-breaking partnership with world-class medication management platform MedAdvisor Solutions (ASX:MDR). The deal with Australia-based MedAdvisor allows Charac to expand it capabilities across Australia, New Zealand and the USA, making components of its app available to a far broader group of pharmacies internationally.

MedAdvisor, through a strategic investment and licencing agreement, will invest up to £1 million over 9-months in Charac for up to a 7.4% shareholding, and the company's CEO Rick Ratliff will join Charac's board as a Non-Executive Director.  MedAdvisor will end operations in the UK, transferring its relationships to Charac.

Through licensing specific components of Charac's platform and integrating them into MedAdvisor's Plus One platform, the partnership will provide tremendous improvements in the delivery of digital pharmacy support, advanced home delivery solutions and eCommerce capabilities.

MedAdvisor has connected with over 3.5 million patients through more than 95% of Australian community pharmacies. It also serves 25% of New Zealand's community pharmacies and works with 33,500 pharmacies in the USA. Globally, MedAdvisor has achieved a milestone of 235 million patients.

Charac's app streamlines pharmacy operations onto a cloud-native platform to relieve time pressure, increase efficiency and drive the growth of independent pharmacies.

The UK's retail pharmacy market is projected to grow from USD$27b in 2022 to $39.59b by 2030. In Australia, revenue in the pharmacies market is close to USD$20b, while in the USA, the market is valued at some USD$527b. All three markets have annual growth projections of between 4%-5%.

Charac is integrated with the NHS, and the company has signed up some 800 pharmacies, with 36,000 patients currently using the app. Charac has previously secured a £1 million investment from the Royal Mail and £1.2 million from the National Pharmacy Association and pharmacy owners.

Santosh Sahu, founder and CEO of Charac, said: "MedAdvisor is an ideal partner for us to help accelerate our international growth plans and pursue our ambitious mission to enable pharmacies to take advantage of the significant opportunities that present themselves."


These press releases may also interest you

at 02:00
QuTEM AB (formerly Vironova BioAnalytics AB), a leading provider of transmission electron microscopy (TEM) services, proudly announces the receipt of GMP (Good Manufacturing Practice) Certificates and Manufacturing Permits for Independent Quality...

at 01:54
FIRST QUARTER (JANUARY - MARCH 2024) Oder intake SEK 238.5 M (206.6)Net sales SEK 257.2 M (230.2)Operating profit SEK 45.8 M (23.7)Profit after tax SEK 36.7 M (17.6)Earnings per share before/after dilution SEK 1.07 (0.51)Cash flow SEK 87.9 M...

at 01:00
In response to valuable feedback from our customers, Luraco Technologies is thrilled to announce the launch of an upgrade to our medical massage chair lineup. We are introducing the Luraco i9 Max Plus Series, a revolution of the i9 Max Series. The i9...

at 00:01
Celltrion USA today announced it will present the two-year results from the extended LIBERTY studies (LIBERTY-CD and LIBERTY-UC) in adult patients...

16 mai 2024
Proteologix, Inc., a privately-held biotechnology company focused on bispecific antibodies for immune-mediated diseases, today announced that it has entered into a definitive agreement to be acquired by Johnson & Johnson for $850 million in cash,...

16 mai 2024
Seelos Therapeutics, Inc. ("Seelos" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system ("CNS") disorders and rare diseases, announced today that it has entered into a...



News published on and distributed by: